Smith Ioana, Kahaleh Michel
Division of Digestive and Liver Diseases, UT Southwestern Medical Center, Dallas, TX.
Department of Medicine.
J Clin Gastroenterol. 2018 Apr;52(4):277-286. doi: 10.1097/MCG.0000000000000966.
The last decade has seen growing insight into the pathophysiology of achalasia, and current treatments decreasing the resting pressure in the lower esophageal sphincter by endoscopic (botulinum toxin injection, pneumatic dilation, peroral endoscopic myotomy) or surgical means (Heller myotomy). Manometry is considered the gold standard to confirm the diagnosis of achalasia. Pneumatic dilation and laparoscopic Heller myotomy have similar effectiveness and are both more successful in patients with type II achalasia. Laparoscopic myotomy when combined with partial fundoplication is an effective surgical technique and has been considered the operative procedure of choice until recently. Peroral endoscopic myotomy is an emerging therapy with promising results since it offers a minimally invasive and efficacious option especially in type III achalasia. However, it remains to be determined if peroral endoscopic myotomy offers long-term efficacy.
在过去十年中,人们对贲门失弛缓症的病理生理学有了更深入的了解,目前的治疗方法通过内镜(肉毒杆菌毒素注射、气囊扩张、经口内镜下肌切开术)或手术手段(Heller肌切开术)降低食管下括约肌的静息压力。食管测压被认为是确诊贲门失弛缓症的金标准。气囊扩张和腹腔镜Heller肌切开术具有相似的疗效,并且在II型贲门失弛缓症患者中都更成功。腹腔镜肌切开术联合部分胃底折叠术是一种有效的手术技术,直到最近一直被认为是首选的手术方法。经口内镜下肌切开术是一种新兴的治疗方法,取得了令人鼓舞的结果,因为它提供了一种微创且有效的选择,尤其是在III型贲门失弛缓症中。然而,经口内镜下肌切开术是否具有长期疗效仍有待确定。